Aurinia Pharmaceuticals stock heads toward November 3, 2026 earnings

Published on 10/17/2026 at 20:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 58.57 million in 2026, below USD 80.45 million estimates. Aurinia Pharmaceuticals stock closed at USD 16.51 on October 16, 2026 at 4:00 p.m. ET, down 1.31 percent versus the prior close.

Upcoming results and valuation

Aurinia Pharmaceuticals is estimated to report third-quarter results on November 3, 2026.
Second-quarter revenue reached USD 58.57 million, below the USD 80.45 million estimate.
Aurinia Pharmaceuticals stock closed at USD 16.51 on Nasdaq on October 16, 2026, down 1.31 percent versus the prior close.
The stock carried a P/E ratio of 7.21 and a market capitalization of USD 2.2 billion.

AUR, CA05156V1022, Illustration mit AI erstellt.

Aurinia Pharmaceuticals is estimated to report third-quarter 2026 results on November 3, 2026, before market open, according to MarketBeat. The date is the next scheduled event in the current calendar. Aurinia Pharmaceuticals stock closed at USD 16.51 on October 16, 2026 at 4:00 p.m. ET on Nasdaq, down 1.31 percent versus the prior close.

Revenue sets the next comparison

The latest reported quarter supplied a mixed operating reference. Revenue reached USD 58.57 million in the second quarter of 2026, while the estimate cited by MarketBeat was USD 80.45 million. The same quarter produced diluted earnings per share of USD 0.28, above the USD 0.24 consensus estimate. The revenue comparison and the earnings comparison point in different directions.

Price sits in a wide range

The Nasdaq range for the session was USD 16.35 to USD 16.81, with 736,105 shares traded against average volume of 851,473 shares. The 52-week range was USD 11.30 to USD 19.25, putting the closing price USD 2.74 below the high and USD 5.21 above the low. MarketBeat lists a 3.50 percent year-to-date gain, based on a USD 15.95 starting level.

Valuation and November date

Aurinia carried a P/E ratio of 7.21 and a market capitalization of USD 2.2 billion as of October 16, 2026. The company does not currently pay a dividend, while the next quarterly report is estimated for November 3, 2026, before market open. The company describes itself as a biotechnology business focused on autoimmune diseases, with Lupkynis as its primary commercial product, according to Aurinia Pharmaceuticals.

Comparison with peers

AUR: minus 1.31 percent, P/E 7.21, market capitalization USD 2.2 billion.
Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion.
GSK (NYSE, USD): plus 1.00 percent, P/E 15.65, market capitalization USD 99.2 billion.

What the next report will test

The November 3 report will place the USD 83.61 million revenue estimate against the USD 58.57 million reported in the second quarter. It will also show whether the USD 0.22 earnings-per-share estimate is below the USD 0.28 delivered in the second quarter. For investors, the key comparison is therefore revenue conversion alongside continued earnings generation.

Nasdaq closing level

The closing price of USD 16.51 on October 16, 2026 was 14.23 percent below the 52-week high of USD 19.25. The company remains positioned between its yearly extremes as the November reporting date approaches.